ClinicalTrials.gg
CompletedNCT00055471Updated Oct 31, 2012Results posted

A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

A Phase 2 interventional study of ZD4054 10 mg and ZD4054 15 mg in Prostatic Neoplasms and Metastases, Neoplasm, sponsored by AstraZeneca. Completed at 2 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-10-31.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.

Enrollment
53rd of 60
22 · median 110
Started
2003
with 7 others
Phase 2
16 of 91
none open now
Registered
1st of 91
by date

Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 53rd largest by enrollment of the 60 interventional ones that give a count, is one of 8 that started in 2003, is one of 16 in phase 2, and was the 1st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Prostatic Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in men with prostate cancer

03

Conditions studied

  • Prostatic Neoplasms
  • Metastases, Neoplasm

Keywords

  • prostate cancer
  • Metastatic prostate cancer
  • bone metastases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men 18 years \& older
  • Confirmed diagnosis of prostate cancer with bone

Exclusion criteria

Exclusion Criteria:

  • No more than 2 prior chemotherapy regimens
  • No radiation, chemotherapy or bisphosphonates in the past 4 weeks
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Enrollment
22 participants (actual)

Study arms

  • Experimental
    ZD4054 10 mg

    1 x 10 mg oral tablets once daily

    Drug: ZD4054 10 mg

  • Experimental
    ZD4054 15 mg

    1 x 10 mg + 2 x 2.5 mg oral tablets once daily

    Drug: ZD4054 15 mg

  • Experimental
    ZD4054 22.5 mg

    2 x 10 mg + 1 x 2.5 mg oral tablets once daily

    Drug: ZD4054 22.5 mg

Interventions

  • 1 x 10 mg oral tablets once daily

    Also known as: Zibotentan,

  • 1 x 10 mg + 2 x 2.5 mg oral tablets once daily

    Also known as: Zibotentan

  • 2 x 10 mg + 2 x 2.5 mg oral tablets once daily

    Also known as: Zibotentan

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLTs)

    DLT is defined as experiencing Common Toxicity Criteria (CTC) grade 3 or 4 headache with onset within 24 h of receiving ZD4054, CTC grade 2 rhinitis leading to the withdrawal of the subject, or other CTC grade 3 or 4 toxicity that was considered to be related to ZD4054 treatment. The numbers of patients with a DLT are reported.

    Time frame: Baseline to Day 29.

Secondary outcomes

  1. Total Prostate Specific Antigen (PSA) Concentration

    Total Prostate Specific Antigen (PSA) concentration at Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2).

    Time frame: Baseline to Day 15.

  2. Change in Total Prostate Specific Antigen (PSA)

    Percentage change in total Prostate Specific Antigen (PSA) (ng/mL) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100

    Time frame: Baseline to Day 15.

  3. Change in Serum Concentration of Bone Alkaline Phosphatase (ALP)

    Percentage change in serum concentration of Bone Alkaline Phosphatase (ALP) (ng/mL) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100

    Time frame: Baseline to Day 15.

  4. Change in Serum Concentration of Procollagen Type I N Propeptide (PINP)

    Percentage change in serum concentration of Procollagen Type I N Propeptide (PINP) (ng/mL) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100

    Time frame: Baseline to Day 15.

  5. Change in Serum Concentration of C-Terminal Telopeptide of Type I Collagen (CTx)

    Percentage change in serum concentration of C-Terminal Telopeptide of Type I Collagen (CTx) (ng/mL) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100

    Time frame: Baseline to Day 15.

  6. Change in Urine Concentration of Type I Collagen-Cross Linked N Telopeptide (NTx)

    Percentage change in urine concentration of Type I Collagen-Cross Linked N Telopeptide (NTx) (nmol BCE/mmol Creatinine) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100

    Time frame: Baseline to Day 15.

07

Results

Posted Aug 31, 2012
Limitations and caveats
One patient received one dose of 22.5 mg and was dose reduced to 15 mg thereafter. This patient was classified into the 15 mg dose group, except for the single dose pharmacokinetic results (not posted).

Participant flow

22 male patients with metastatic prostate cancer and rising Prostate Specific Antigen (PSA) levels were recruited from 11th June 2003 (last subject completed on 31st October 2005). This study was conducted in 2 centres in the United States.

Period 1: Dose Escalation Period
Participant flow — Period 1: Dose Escalation Period
MilestoneZD4054 10 mgZD4054 15 mgZD4054 22.5 mg
Started3103
Completed380
Not completed023
Withdrew: Adverse event012
Withdrew: Erroneously reported discont. criteria001
Withdrew: Disease progression010
Period 2: Extension Period
Participant flow — Period 2: Extension Period
MilestoneZD4054 10 mgZD4054 15 mgZD4054 22.5 mg
Started360
Completed360
Not completed000

Outcome measures

PrimaryDose Limiting Toxicities (DLTs)

DLT is defined as experiencing Common Toxicity Criteria (CTC) grade 3 or 4 headache with onset within 24 h of receiving ZD4054, CTC grade 2 rhinitis leading to the withdrawal of the subject, or other CTC grade 3 or 4 toxicity that was considered to be related to ZD4054 treatment. The numbers of patients with a DLT are reported.

Time frame:
Baseline to Day 29.
Reported as:
Number · Participants
Dose Limiting Toxicities (DLTs)
ParticipantsZD4054 10 mgZD4054 15 mgZD4054 22.5 mg
Dose Limiting Toxicities (DLTs)002
SecondaryTotal Prostate Specific Antigen (PSA) Concentration

Total Prostate Specific Antigen (PSA) concentration at Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2).

Time frame:
Baseline to Day 15.
Reported as:
Geometric mean · ng/ml
Total Prostate Specific Antigen (PSA) Concentration
ng/mlZD4054 10 mgZD4054 15 mgZD4054 22.5 mg
Total Prostate Specific Antigen (PSA) Concentration98.454 (78.00 to 142.60)62.366 (6.00 to 448.90)56.550 (36.80 to 86.90)
SecondaryChange in Total Prostate Specific Antigen (PSA)

Percentage change in total Prostate Specific Antigen (PSA) (ng/mL) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100

Time frame:
Baseline to Day 15.
Reported as:
Mean · Percentage Change
Change in Total Prostate Specific Antigen (PSA)
Percentage ChangeZD4054 10 mgZD4054 15 mgZD4054 22.5 mg
Change in Total Prostate Specific Antigen (PSA)2.235 ± 15.44510.986 ± 21.34518.404 ± 30.132
SecondaryChange in Serum Concentration of Bone Alkaline Phosphatase (ALP)

Percentage change in serum concentration of Bone Alkaline Phosphatase (ALP) (ng/mL) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100

Time frame:
Baseline to Day 15.
Reported as:
Mean · Percentage Change
Change in Serum Concentration of Bone Alkaline Phosphatase (ALP)
Percentage ChangeZD4054 10 mgZD4054 15 mgZD4054 22.5 mg
Change in Serum Concentration of Bone Alkaline Phosphatase (ALP)-6.161 ± 9.616-9.197 ± 12.220-9.182 ± 10.644
SecondaryChange in Serum Concentration of Procollagen Type I N Propeptide (PINP)

Percentage change in serum concentration of Procollagen Type I N Propeptide (PINP) (ng/mL) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100

Time frame:
Baseline to Day 15.
Reported as:
Mean · Percentage Change
Change in Serum Concentration of Procollagen Type I N Propeptide (PINP)
Percentage ChangeZD4054 10 mgZD4054 15 mgZD4054 22.5 mg
Change in Serum Concentration of Procollagen Type I N Propeptide (PINP)7.865 ± 14.62520.681 ± 44.217113.012 ± 51.302
SecondaryChange in Serum Concentration of C-Terminal Telopeptide of Type I Collagen (CTx)

Percentage change in serum concentration of C-Terminal Telopeptide of Type I Collagen (CTx) (ng/mL) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100

Time frame:
Baseline to Day 15.
Reported as:
Mean · Percentage Change
Change in Serum Concentration of C-Terminal Telopeptide of Type I Collagen (CTx)
Percentage ChangeZD4054 10 mgZD4054 15 mgZD4054 22.5 mg
Change in Serum Concentration of C-Terminal Telopeptide of Type I Collagen (CTx)-13.832 ± 19.00344.855 ± 94.87620.386 ± 31.094
SecondaryChange in Urine Concentration of Type I Collagen-Cross Linked N Telopeptide (NTx)

Percentage change in urine concentration of Type I Collagen-Cross Linked N Telopeptide (NTx) (nmol BCE/mmol Creatinine) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100

Time frame:
Baseline to Day 15.
Reported as:
Mean · Percentage Change
Change in Urine Concentration of Type I Collagen-Cross Linked N Telopeptide (NTx)
Percentage ChangeZD4054 10 mgZD4054 15 mgZD4054 22.5 mg
Change in Urine Concentration of Type I Collagen-Cross Linked N Telopeptide (NTx)-25.213 ± 15.3892.154 ± 41.900-5.942 ± 34.344

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ZD4054 10 mg—0/3 (0%)3/3 (100%)
ZD4054 15 mg—2/10 (20%)10/10 (100%)
ZD4054 22.5 mg—2/3 (66.7%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventZD4054 10 mgZD4054 15 mgZD4054 22.5 mg
HeadacheNervous system disorders0/30/101/3
Intraventricular HaemorrhageNervous system disorders0/30/101/3
SyncopeNervous system disorders0/30/101/3
Rectal HaemorrhageGastrointestinal disorders0/31/100/3
DyspnoeaRespiratory, thoracic and mediastinal disorders0/31/100/3
Pleural EffusionRespiratory, thoracic and mediastinal disorders0/31/100/3
Back PainMusculoskeletal and connective tissue disorders0/31/100/3
Pitting OedemaGeneral disorders0/31/100/3
Most frequent other events
Showing 10 of 68
Most frequent other events
EventZD4054 10 mgZD4054 15 mgZD4054 22.5 mg
FatigueGeneral disorders0/34/103/3
HeadacheNervous system disorders2/39/103/3
Oedema PeripheralGeneral disorders0/39/101/3
ArthralgiaMusculoskeletal and connective tissue disorders1/32/102/3
Pain In ExtremityMusculoskeletal and connective tissue disorders1/31/102/3
Sinus CongestionRespiratory, thoracic and mediastinal disorders0/32/102/3
AnaemiaBlood and lymphatic system disorders1/30/100/3
TinnitusEar and labyrinth disorders1/30/100/3
CataractEye disorders1/30/100/3
ConstipationGastrointestinal disorders1/30/100/3

Baseline characteristics

Age Continuous
Age Continuous(Years)ZD4054 10 mgZD4054 15 mgZD4054 22.5 mgTotal
Overall72.3 ± 3.2164.6 ± 9.7266.3 ± 8.0866.4 ± 8.72
Sex: Female, Male
Sex: Female, Male(Participants)ZD4054 10 mgZD4054 15 mgZD4054 22.5 mgTotal
Female0000
Male310316
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ZD4054 10 mgZD4054 15 mgZD4054 22.5 mgTotal
Caucasian39315
Black0101
Oriental0000
Other0000
Height
Height(Centimeters (cm))ZD4054 10 mgZD4054 15 mgZD4054 22.5 mgTotal
Mean177.33 ± 4.51177.10 ± 8.02176.33 ± 5.03177 ± 6.69
Weight
Weight(Kilograms (kg))ZD4054 10 mgZD4054 15 mgZD4054 22.5 mgTotal
Mean87.33 ± 19.035107.8 ± 21.060103.00 ± 35.595103.06 ± 23.405
08

Study locations

2 sites
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Madison, Wisconsin, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2003, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 6 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2003
First posted
Mar 4, 2003
Start
Jun 2003
Primary completionActual
Oct 2005
CompletionActual
Oct 2005
Results first posted
Aug 31, 2012
Last update
Oct 31, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00055471
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 4, 2003
Start date
Jun 2003
Primary completion
Oct 2005
Completion
Oct 2005
Results posted
Aug 31, 2012
Last update
Oct 31, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZD4054

Start the discussion